Purpose: Transperineal template prostate mapping biopsy is an increasingly used method of procuring tissue from men with suspected prostate cancer. We report patient related outcome measures and adverse events in men in the PICTURE trial (ClinicalTrials.gov NCT01492270) who underwent this diagnostic test. Materials and Methods: A total of 249 men underwent multiparametric magnetic resonance imaging followed by transperineal template prostate mapping biopsy as a validation study. Functional outcomes before and after transperineal template prostate mapping were prospectively collected and recorded with questionnaires, including the I-PSS (International Prostate Symptom Score), the I-PSS-QoL (Quality of Life), the IIEF-15 (International Index of Erectile Function-15) and the EPIC (Expanded Prostate Cancer Index Composite) urinary function. Results: Mean age was 62 years, median prostate specific antigen was 6.8 ng/ml and median gland size was 37 ml. At transperineal template prostate mapping biopsy a median of 49 cores (IQR 40e55) were taken. Mean time to complete the post-procedure patient related outcome measure questionnaires was 46 days. Adverse events included post-procedure acute urinary retention in 24% of patients, rectal pain in 26% and perineal pain in 41%. Transperineal template prostate mapping biopsy resulted in a statistically significant increase in scores on the I-PSS from 10.9 to 11.8 (p ¼ 0.024) and the I-PSS-QoL from 1.57 to 1.76 (p ¼ 0.03). The IIEF-15 erectile function score decreased by 23.2% from 47.7 to 38.7 (p <0.001). Significant deterioration was noted in all 5 of IIEF-15 functional domains, including erectile and orgasmic function, sexual desire, and intercourse and overall satisfaction (p <0.001). EPIC urinary scores showed no overall change from baseline. Conclusions: Transperineal template prostate mapping biopsy causes a high urinary retention rate and a detrimental impact on genitourinary functional outcomes, including deterioration in urinary flow and sexual function. Our findings can be used to ensure adequate counseling about transperineal template prostate mapping biopsies. The results point to a need for strategies such as multiparametric magnetic resonance imaging and targeted biopsies to minimize the harms of transperineal template prostate mapping biopsy.
MEN who undergo TRUS guided prostate cancer biopsy can sometimes be misclassified due to the diagnostic inaccuracy of this test. 1, 2 As a result in many health care settings transperineal template sector or prostate mapping biopsies, or TTPM biopsies are increasingly performed as a second biopsy technique in men with an initial TRUS biopsy for which diagnostic uncertainty remains.
3,4 TTPM biopsy is an accurate technique but it is more invasive in that multiple biopsies (an average of 30 to 60 cores) are taken with the patient under general or spinal anesthesia. The impact of this test on QoL has been poorly reported. The clinical risks associated with prostate biopsy include hemorrhagic complications such as hematuria, hemospermia, and rectal and perineal bleeding.
5 TRUS biopsy also incurs a significant sepsis risk and the promotion of global antibiotic resistance. 6 Traditional clinical ways of measuring health and the effects of treatment are increasingly accompanied by PROMs. 7 These measures are directly reported by the patient without clinician interpretation of the patient response. 8 PROMs have become the new standard for evaluating the patient experience and they are increasingly being used to shape the way that health care is funded, provided and managed. 7 Studies using PROMs for various modalities of prostate cancer treatments across all grades of disease, including active surveillance, watchful waiting, brachytherapy, radical radiotherapy and prostatectomy, have also been extensively reported in the literature. 9e12 PICTURE (ClinicalTrials.gov NCT01492270) was a paired cohort confirmatory study designed to assess the diagnostic accuracy of mpMRI in men requiring repeat biopsy.
13,14 It prospectively provided evidence of the diagnostic performance of mpMRI targeted biopsies and validated this index test against the reference test of TTPM biopsy.
We report adverse events as well as changes in PROMs in the largest series of men who underwent TTPM biopsy in the PICTURE trial.
13,14

MATERIAL AND METHODS
Study Design and Participants
The PICTURE trial design, baseline demographic and clinical results were previously reported in detail (see Appendix and table 1). 13,14 Ethics committee approval for the study was granted by the London City Road and Hampstead National Research Ethics Committee (reference 11/LO/1657). The study opened to recruitment on January 11, 2012, and completed recruitment on January 29, 2014. All men had previously undergone TRUS biopsy. The study was done at a single center by 3 experienced operating surgeons. Before TTPM biopsy the patients received intravenous antibiotics in a combination of intravenous gentamicin (120 mg) and cefuroxime (1.5 gm).
Briefly, the mapping protocol used for TTPM biopsy was performed using 5 mm intervals to validate a new diagnostic test. This biopsy was obtained using core needles inserted via a brachytherapy grid fixed on a stepper. In most prostates 2 biopsies at each grid point were required to sample the full craniocaudal gland length. After the procedure the patients were given a metronidazole (500 mg) suppository and analgesics in the form of nonsteroidal anti-inflammatory and paracetamol/codeine combinations. Routine oral antibiotics were not administered to the patients after the procedure.
Patient Reported Outcome Measures
Adverse events following TTPM were monitored and recorded, including the established and recognized side effects of this procedure. Validated PROM questionnaires included the I-PSS, the I-PSS-QoL, the IIEF-15 and the EPIC urinary function questionnaire administered before and after TTPM biopsies (supplementary Appendixes 1 to 3, http://jurology. com/).
Data Collection and Analysis
All participants were provided with paper questionnaires at the initial trial recruitment. Questionnaires were completed privately by the patients without any of the clinical or research team present. All participants were provided with a paper questionnaire pack by post and asked to return it via a prepaid postal service or during the next clinical consultation, which was to 6 to 8 weeks after TTPM biopsy. Only men who completed each questionnaire in full before and after biopsy were included in the study for further analysis of each validated questionnaire type. All questionnaire responses and data were entered in a SPSSÒ Statistics, version 24 database.
Descriptive statistics were used to describe the baseline and followup values of all parameters. For PROMs the paired t-test was applied to evaluate the change from baseline for each measure. All statistical tests were 2-tailed with p <0.05 considered statistically significant. All analyses were done with SPSS Statistics, version 24.0. 
RESULTS
A total of 330 men were enrolled in the study. After 81 withdrawals due to a gland greater than 80 ml in 61 men, patient choice in 9, a medical reason in 4 and a miscellaneous reason in 7 the mpMRI and TTPM biopsies were completed in 249 men. Table 1 summarizes patient demographics and histological characteristics. Men eligible for analysis had a mean age of 62 years, median prostate specific antigen 6.8 ng/ml (IQR 4.8e9.8), a median of 1 previous TRUS biopsy (IQR 1e2) and a median gland size of 37 ml (IQR 26.8e50.0). At TTPM biopsy a median of 49 cores (IQR 40e55) were taken. The mean time to complete the post-procedure PROM questionnaires was 46 days. Of the 249 men in the PICTURE study 13, 14 203, 203, 164 and 176 completed the I-PSS, the I-PSS-QoL, the IIEF-15 and the EPIC urinary questionnaires in full before and after the TTPM biopsies for a response rate of 81.5%, 81.5%, 65.8% and 70.1%, respectively.
Adverse Events
Adverse events were captured in 236 of the 249 cases (94.8%) a median AE SD of 38 AE 56 days after biopsy (table 2) . Hematuria developed in 220 of the 249 men (88.4%) after TTPM biopsy of whom 2 (0.8%) required hospital admission due to clot urinary retention. Poor urine flow was reported in 108 of the 249 men (43.8%).
Following TTPM biopsy acute urinary retention developed in 56 of the 249 men (22.55%). The urethral catheter remained in situ for an average of 8 days prior to successful removal. No patient remained catheter dependent more than 28 days or required transurethral resection after TTPM biopsy.
Post-procedure rectal and perineal pain, and perineal bruising were reported in 59 (23.7%), 95 (38.1%) and 136 of the 249 cases (54.6%), respectively. Urinary tract infection developed in 23 men (9.2%) and perineal skin infection developed in 8 (3.2%). No patients were admitted to the hospital with postprocedure urinary sepsis.
Serious related adverse events resulting from TTPM biopsy developed in 8 of the 249 men (3.2%).
These serious events were urinary clot retention in 2 men, acute urinary retention in 5, including immediately to less than 24 hours in 3 and longer than 24 hours in 2 (days 14 and 19), and hospital admission in 1 for monitoring due to a slow urinary flow. In the latter case a catheter was not required.
Urinary Function
No men with a catheter in situ completed the PROM questionnaires. TTPM biopsy resulted in a statistically significant increase in the I-PSS score from 10.9 to 11.8 (2-tailed t-test p ¼ 0.024, table 3). With regard to the baseline urinary symptoms score 33.5%, 54.8% and 11.7% of patients were in the I-PSS mild, moderate and severe symptom groups, respectively. There was no major change in these values after TTPM biopsy with 28.6%, 57.8% and 13.6% of cases in the mild, moderate and severe categories, respectively. TTPM biopsy also resulted in a statistically significantly sustained increase in the I-PSS-QoL score from 1.57 to 1.76 (2-tailed t-test p ¼ 0.03, table 3).
Sexual Function
There was a statistically significant negative impact on sexual function with erectile function scores on the IIEF-15 decreasing from 47.7 to 38.7 (2-tailed t-test p <0.001, 
DISCUSSION
In summary, our study shows that TTPM biopsy has high adverse event rates, including a high postoperative urinary retention rate in nearly 1 of 4 men. Furthermore, we found a sustained detrimental impact on genitourinary function, including deterioration in lower urinary tract symptoms and all aspects of sexual function, which persisted for several weeks. Our study adds to the literature on PROMs after prostate biopsy performed via the transperineal route.
15e17 Our study differs in that to our knowledge it is the first report of PROMs in men who exclusively underwent TTPM biopsy following a prior TRUS biopsy.
The first prospective collection of PROM data on transperineal biopsies was reported by Wadhwa et al. 17 They only evaluated short-term PROMs at 7 to 14 days after transperineal prostate biopsy in 201 men. They found that transperineal prostate biopsy resulted in a significant detrimental change in the erectile function score, as in our study, but there was no difference in the I-PSS and the I-PSS-QoL scores. The major limitation of using that study as a comparator to our series was the heterogeneous nonstandardized method of transperineal prostate biopsy across various centers, which was not exclusively performed in a template mapping manner.
Bhatt et al reported on a cohort of 27 patients who underwent TTPM biopsy with a postoperative pain outcome and a hematuria rate that were similar to those in our study. 15 This group also reported significant deterioration in the sexual function score. This was longer in duration due to the median followup questionnaire completion of 37 weeks in their study, significantly longer than our shorter followup of 6 to 8 weeks.
Pepe and Pennisi reported on 1,050 men who underwent transperineal prostate biopsy as well as sexual adverse events in these men. 18 Transperineal prostate biopsy did not significantly worsen erectile function 3 to 6 months after the procedure. However, they administered the shorter form of the IIEF questionnaire and also obtained fewer cores than in our study, which included 5 mm mapping biopsy of each prostate. In our study TTPM biopsies would include those grid points 5 mm from the urethra but biopsies were not taken through the midline grid points anterior to the urethra so as not to traverse the urethra. We think that the high retention rate was due to biopsy related swelling from the high number of cores.
The implementation of PROMs has transitioned from being primarily descriptive in nature to producing actionable findings. 19 Health care policy makers now rely on these measures to compare outcomes among institutions and determine whether specific procedures are worthwhile to support. 20 Our findings can be used to ensure adequate counseling about TTPM biopsies. Results point to the need for strategies such as mpMRI and targeted biopsies to minimize the harms of TTPM biopsy.
Nonetheless, TTPM biopsy has advantages over TRUS biopsy with lower infection and sepsis rates, and improved diagnostic information. 1 Furthermore, TRUS biopsy has been shown be associated with significant pain and distress, and it is a major causative factor of the globally increasing incidence of antimicrobial resistance to microorganisms in the rectal flora.
21e23 Performing TTPM biopsy on a larger scale would clearly be expensive and resource intensive. In addition, as we found, it would result in significant toxicity. The results of the PROMIS study (ClinicalTrials.gov NCT01292291) have now provided level 1 evidence for the application of prebiopsy mpMRI. 1 This is now the emerging standard of care at major institutions across the United Kingdom and beyond with other centers closely following suit due to a national strategy to deliver this change. 24 The combination of prebiopsy MRI and targeted biopsies has resulted in the use of image guided transperineal prostate biopsy as an increasing method of sampling in men with suspected prostate cancer. 25 Targeted transperineal biopsies with limited sampling means fewer cores than TTPM biopsy, minimal toxicity and a low retention rate of 1% or less with the procedure done with the patient under local anesthesia or conscious sedation. 24 TTPM biopsy can be performed in equivocal cases in which imaging may be contraindicated or unclear, or diagnostic doubt remains for another reason.
Avoidance of TTPM and replacement with a targeted transperineal approach would also result in improved efficiency and optimization of the diagnostic pathway. Limiting the number of cores would result in efficiency and cost savings. It would liberate more operative time, reduce the number of consumables and decrease the burden of technical time and workload on pathology departments. 26, 27 This would additionally release more resources which could potentially be steered toward a greater number of men in a contemporary prostate cancer diagnostic pathway in a more timely manner. In addition to the unfavorable PROMs, these potential outcomes are important issues that should be highlighted when engaging stakeholders in units who are in the process of or are planning to restructure diagnostic pathways to a more up-to-date and patient centered model. Our study limitations include the exclusion of prostate glands larger than 80 cc due to the inability to accurately sample the lateral and anterior parts of the gland due to the bony pelvis. However, it is likely that the retention rate would have been much higher if larger glands had been included.
We did not assess the rate of post-procedural hemospermia or hematochezia. Our PROM response rate was not complete but it was higher than in most comparable studies in which the response rate was 51.6% to 60%. 15, 17 In regard to urinary function following TTPM biopsy, we believe that while these differences are small, they are clinically relevant, given the correlating changes in QoL scores.
Finally, the PICTURE study did not incorporate longitudinal followup beyond the 6 to 8-week period.
13,14 This is clearly needed to assess the time required by patients to return to baseline genitourinary function after TTPM biopsy.
CONCLUSIONS
Our study revealed that men who undergo TTPM biopsy will experience significant and sustained detrimental erectile and urinary function with a high risk of requiring a urinary catheter due to urinary retention. Patients and their physicians should be aware of these detrimental effects, and look to incorporate targeting and limited sampling to maintain the accuracy and the benefits of a low infection rate conferred by transperineal biopsy. 
